EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Effect of empagliflozin on urinary albumin excretion and hypoxic biomarkers in early diabetic kidney disease: A randomised double‐blind, placebo‐controlled trial

Hisashi Makino iD, Masato Kasahara, Ryuzo Takashima, Shu Kasama, Naoki Ozu iD, Hyohun Park, Qingxing Chen, Kazuhiko Tsuruya, Mayu Tochiya, Yoko Omura-Ohata, Tamiko Tamanaha, Michio Noguchi und 3 weitere

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.70485 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Hisashi Makino und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Diabetes and Lipid Metabolism, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan. Hauptthemen laut MEDLINE: Glucosides, Benzhydryl Compounds, Diabetic Nephropathies, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Boehringer Ingelheim, Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The precise mechanism of sodium glucose co‐transporter 2 (SGLT2) inhibitor on reno‐protective effect has been still unclear. In this study, we hypothesised that SGLT2 inhibitor prevents diabetic kidney disease via reduction of hypoxia‐induced factors. Materials and Methods In this multicenter, prospective, randomised, double blinded clinical trial, people with type 2 diabetes and microalbuminuria were randomised equally to empagliflozin (10 mg/day) ( n = 40) and placebo ( n = 39) and followed 24 weeks. The primary endpoint was change in urinary albumin creatinine ratio (ACR) and urinary liver type fatty acid binding protein (L‐FABP) excretion from baseline to 24 weeks. Major secondary outcome was change in serum vascular endothelial growth factor (VEGF), angiopoietin‐like proteins 2 (ANGPTL2), angiopoietin‐like proteins 4 (ANGPTL4), and adrenomedullin (AM) levels.

Results

Although the reduction of ACR was significantly greater in the empagliflozin group than the placebo group at 4 and 12 weeks, the difference of change at 24 weeks between the two groups was not statistically significant (Empagliflozin group—Placebo group: −0.3643, 95% CI: −0.7571 to 0.0285, p = 0.0686). There was no difference in urinary L‐FABP excretion between the empagliflozin and placebo groups. Serum VEGF and ANGPTL2 decreased significantly more in the empagliflozin group, whereas there were no significant differences in AM and ANGPTL4.

Conclusions

These results demonstrated that empagliflozin partially suppressed the hypoxia‐induced angiogenic factors overproduction in addition to a declining trend in ACR in the early stage of diabetic kidney disease, which might contribute to the mechanisms of reno‐protective effects of this agent (jRCTs051200147).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlucosidesBenzhydryl CompoundsDiabetic NephropathiesDiabetes Mellitus, Type 2AlbuminuriaSodium-Glucose Transporter 2 InhibitorsHumansDouble-Blind MethodFemaleMaleBiomarkersMiddle AgedFatty Acid-Binding ProteinsProspective StudiesVascular Endothelial Growth Factor AAgedAngiopoietin-Like Protein 2HypoxiaAngiopoietin-Like Protein 4Angiopoietin-like Proteins

Stichwörter der Autor:innen

clinical trialdiabetic nephropathyempagliflozinrandomised trialtype 2 diabetes

Substanzen

GlucosidesBenzhydryl CompoundsempagliflozinBiomarkersSodium-Glucose Transporter 2 InhibitorsFatty Acid-Binding ProteinsVascular Endothelial Growth Factor AANGPTL2 protein, humanAngiopoietin-Like Protein 2Angiopoietin-Like Protein 4

Autor:innen und Institutionen

  • Division of Diabetes and Lipid Metabolism, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan.
  • Institute for Clinical and Translational Science, Nara Medical University Hospital, Kashihara, Nara, Japan.
  • Department of Internal Medicine, Kyowakai Hospital, Suita, Osaka, Japan.
  • Department of Diabetes and Endocrinology, Takatsuki General Hospital, Takatsuki, Osaka, Japan.
  • Department of Nephrology, Nara Medical University, Kashihara, Nara, Japan.
  • Division of Arrhythmia, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan.

ORCID-Profile: Hisashi Makino, Naoki Ozu

Förderung

  • Boehringer Ingelheim
  • Eli Lilly and Company

Zitieren

APA

Makino, H., Kasahara, M., Takashima, R., Kasama, S., Ozu, N., Park, H., Chen, Q., Tsuruya, K., Tochiya, M., Omura-Ohata, Y., Tamanaha, T., Noguchi, M., Aiba, T., Yoshihara, F., & Hosoda, K. (2026). Effect of empagliflozin on urinary albumin excretion and hypoxic biomarkers in early diabetic kidney disease: A randomised double‐blind, placebo‐controlled trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70485

Vancouver

Makino H, Kasahara M, Takashima R, Kasama S, Ozu N, Park H, et al. Effect of empagliflozin on urinary albumin excretion and hypoxic biomarkers in early diabetic kidney disease: A randomised double‐blind, placebo‐controlled trial. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70485

BibTeX
@article{Makino2026,
  author = {Makino, Hisashi and Kasahara, Masato and Takashima, Ryuzo and Kasama, Shu and Ozu, Naoki and Park, Hyohun and Chen, Qingxing and Tsuruya, Kazuhiko and Tochiya, Mayu and Omura-Ohata, Yoko and Tamanaha, Tamiko and Noguchi, Michio and Aiba, Takeshi and Yoshihara, Fumiki and Hosoda, Kiminori},
  title = {Effect of empagliflozin on urinary albumin excretion and hypoxic biomarkers in early diabetic kidney disease: A randomised double‐blind, placebo‐controlled trial},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.70485}
}
Kostenlos starten →